Drug Search Results
More Filters [+]

Faldaprevir

Alternative Names: faldaprevir, bi201335, bi 201335
Latest Update: 2023-09-30
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Faldaprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis C, Chronic|Hepatitis A|Hepatitis C|Acquired Immunodeficiency Syndrome|HIV Infections|Liver Cirrhosis

Phase 2: Hepatitis C|Hepatitis C, Chronic|Hepatitis A

Phase 1: Healthy Volunteers|Hepatitis A|Hepatitis C, Chronic|Hepatitis C|Kidney Diseases|HIV Infections|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TRK-450-0203

P2

Completed

Hepatitis C, Chronic|Hepatitis A

2017-09-01

TRK-450-0201

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2016-12-01

2012-003534-17

P2

Completed

Hepatitis C, Chronic

2016-06-08

NCT01608737

P3

Withdrawn

Hepatitis A|Hepatitis C, Chronic

2015-10-01

Recent News Events